Efficiency of Botulinum Toxin Type-a in the Management of the Myofascial Pain

Hacettepe University

Status: Completed

Conditions: Myofascial Pain - Dysfunction Syndrome of TMJ

Treatments: Drug: Botulinum Toxin A (Botox )

Study type: Interventional

Funder types: Other

Identifiers

NCT06840730

KA-23004

Details and patient eligibility

About

**Study Title:** Investigation of the Relationship Between Clinical Outcomes and Pain Mediators in the Treatment of Masticatory Muscle Disorders Associated with Myospasm Using Onabotulinum Toxin A

**Study Importance:** Temporomandibular disorders (TMD) are a major cause of chronic orofacial pain, affecting 5-12% of the population. Masticatory muscle disorders (MMD) are a common subgroup of TMD, ranging from localized myalgia to fibromyalgia. Myospasm is characterized by sudden pain, malocclusion, and limited jaw movement, while myalgia includes localized, myofascial, and referred pain patterns. The etiology of MMD is complex, involving neuromuscular dysfunction, inflammation, and increased acetylcholine activity at the neuromuscular junction. Various mediators, including CGRP, substance P, and inflammatory cytokines, play a role in sensitization and pain perception.

**Objective:** This study aims to evaluate the effectiveness of onabotulinum toxin A (BTX-A) in patients with MMD who have not responded to conventional non-invasive treatments. It hypothesizes that BTX-A reduces pain by decreasing inflammatory cytokines and neuropeptides associated with pain.

**Methodology:**

• **Study Design:** Prospective observational clinical study.
• **Participants:** Patients diagnosed with MMD based on RDC/TMD criteria, who have not improved with conventional treatments.
• **Exclusion Criteria:** Conditions such as pregnancy, metabolic disorders, trauma, systemic diseases, and medication use that could interfere with results.
• **Intervention:** BTX-A will be injected into the masseter and temporalis muscles (30 and 15 units per side, respectively) following a standardized protocol.
• **Data Collection:**
• Before (T0) and one month after (T1) treatment.
• Clinical assessments include maximum mouth opening (MMO), pain levels (VAS), and oral health impact profile (OHIP-14).
• Blood and saliva samples will be analyzed for IL-1, IL-6, TNF-α, CGRP, and NGF using ELISA.
• **Statistical Analysis:** Dependent t-test or Wilcoxon signed-rank test will be used to compare pre- and post-treatment values. Correlations between biomarker levels and pain reduction will be analyzed using Spearman correlation.

**Expected Outcomes:**

• Significant reduction in pain and improvement in MMO.
• Decreased levels of inflammatory and neuropeptide biomarkers.
• Evaluation of saliva as a non-invasive medium for biomarker analysis, potentially guiding future diagnostic and monitoring strategies.

**Significance:** This study provides insights into the pathophysiology of MMD and the efficacy of BTX-A in pain management, potentially offering an alternative therapeutic approach for patients resistant to conventional treatments.

Enrollment: 20 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria: Patients diagnosed with MMD based on RDC/TMD criteria, who have not improved with conventional treatments.

Exclusion Criteria:Conditions such as pregnancy, metabolic disorders, trauma, systemic diseases, and medication use that could interfere with results

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

20 participants in 1 patient group

botulinum toxin

Experimental group

Description:

TX-A will be injected into the masseter and temporalis muscles (30 and 15 units per side, respectively) following a standardized protocol.

Treatment:

Drug: Botulinum Toxin A (Botox )